Something of interest, Goldfinch launching Ph2 trial for diabetic nephropathy & FSGS:
https://www.businesswire.com/news/home/20200908005049/en/Goldfinch-Bio-Initiates-Phase-2-Clinical-Trial-Evaluating-Novel-Drug-Candidate-GFB-887-as-a-Precision-Medicine-for-Patients-with-Kidney-Diseases
Goldfinch are already in collaboration with Gilead, with a $55 million upfront payment (was in phase 1) and the deal is worth up to US$1.95 billion for kidney disease discovery, and this doesn’t include the above trial drug GFB-887 or GFB-024 which Goldfinch will retain all rights for.
https://www.gilead.com/news-and-press/press-room/press-releases/2019/5/gilead-sciences-and-goldfinch-bio-announce-strategic-collaboration-to-develop-novel-therapies-for-kidney-disease
So on successful Ph2b results on Monday, I think the Unicorn theory is entirely possible.
Have a great day all
Ann: Trading Halt, page-251
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.8¢ |
Change
-0.008(2.00%) |
Mkt cap ! $206.3M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $524.0K | 1.400M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 205414 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 4484 | 2 |
View Market Depth
| Last trade - 15.50pm 15/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |